BTIG Research Increases LifeMD (NASDAQ:LFMD) Price Target to $14.00

LifeMD (NASDAQ:LFMD) had its target price lifted by BTIG Research from $13.00 to $14.00 in a research report sent to investors on Tuesday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Separately, HC Wainwright increased their price target on LifeMD from $10.00 to $12.00 and gave the stock a buy rating in a research note on Thursday, January 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and an average target price of $10.40.

LifeMD Trading Up 10.4 %

Shares of LifeMD stock opened at $11.95 on Tuesday. LifeMD has a 1 year low of $1.40 and a 1 year high of $12.05. The firm has a market cap of $482.42 million, a PE ratio of -17.07 and a beta of 1.43. The stock has a fifty day moving average price of $9.42 and a 200-day moving average price of $7.76. The company has a debt-to-equity ratio of 3.22, a current ratio of 1.22 and a quick ratio of 1.15.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Monday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business had revenue of $44.86 million for the quarter, compared to analysts’ expectations of $40.65 million. Equities research analysts anticipate that LifeMD will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LFMD. G2 Investment Partners Management LLC boosted its stake in LifeMD by 23.9% in the 4th quarter. G2 Investment Partners Management LLC now owns 688,050 shares of the company’s stock worth $5,704,000 after purchasing an additional 132,850 shares during the period. Cantor Fitzgerald L. P. bought a new position in LifeMD in the 4th quarter worth about $653,000. Tower Research Capital LLC TRC boosted its stake in LifeMD by 266.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after purchasing an additional 3,348 shares during the period. Hsbc Holdings PLC bought a new position in LifeMD in the 4th quarter worth about $815,000. Finally, Jump Financial LLC boosted its stake in LifeMD by 50.2% in the 4th quarter. Jump Financial LLC now owns 111,738 shares of the company’s stock worth $926,000 after purchasing an additional 37,339 shares during the period. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.